Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First in human, study of KM 023 for Olmstead syndrome

Next Previous
Trial Profile

A First in human, study of KM 023 for Olmstead syndrome

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ainuovirine (Primary)
  • Indications Skin disorders
  • Focus Adverse reactions; First in man

Most Recent Events

  • 03 Jun 2025 According to Kamari Pharma media release, company announced the closing of a $23 million Series A financing. The round was co-led by new investor BRM Group and existing investor Pontifax with participation from additional investors. Proceeds will be used to advance lead program KM023 a first-in-class oral TRPV3 inhibitor, into clinical development for the treatment of three rare genetic skin diseases, Olmsted syndrome, severe keratoderma and ichthyosis.
  • 23 May 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top